Advertisement News Archives - Page 1578 of 5245 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 18, 2026

Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer

The European Commission (EC) has granted marketing authorisation for Revolution Medicines’ Rasonque (daraxonrasib) to treat adult patients with metastatic pancreatic adenocarcinoma who have undergone at least one systemic therapy earlier.

Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer